- cafead   May 13, 2021 at 12:02: PM
via Merck & Co.'s immunotherapy Keytruda kept tumors from returning in a Phase 3 study of patients with a tough-to-treat form of early-stage breast cancer, positioning the drugmaker to again seek approval after regulators rejected the treatment earlier this year.
article source
article source